검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Rilotumumab (Rilotumumab) SWOG Cancer Research Network·Recurrent Squamous Cell Lung Carci… ORR 21%·t½ 5.6 h |
|---|---|
Overview Program | Rilotumumab |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Squamous Cell Lung Carcinoma |
Overview Indication | Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
PK/PD Half-life | 5.6 h |
Toxicology Major finding | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: C… |
Clinical Primary efficacy | ORR 21% |
Clinical ORR | 21% |
Clinical Result source | ClinicalTrials.gov NCT00788957 |
Clinical Data Tier / Score | A · 7 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Rilotumumab (Rilotumumab) SWOG Cancer Research Network·Recurrent Squamous Cell Lung Carci… ORR 21%·t½ 5.6 h |
|---|---|
Overview Program | Rilotumumab |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Squamous Cell Lung Carcinoma |
Overview Indication | Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
PK/PD Half-life | 5.6 h |
Toxicology Major finding | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: C… |
Clinical Primary efficacy | ORR 21% |
Clinical ORR | 21% |
Clinical Result source | ClinicalTrials.gov NCT00788957 |
Clinical Data Tier / Score | A · 7 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
추천 비교
추천 비교